NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours

NUCLIDIUM and PharmaLogic Holdings announced that they have entered into a strategic collaboration agreement for the production and clinical supply of 61Cu in the United States to accelerate the development of NUCLIDIUM’s theranostic pipeline.